AltruBio Inc.
http://www.abgenomics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AltruBio Inc.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
Finance Watch: Biotech Venture Capital Had Its Biggest Quarter Ever
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
Recent Financings Of Private Companies, September 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
AbGenomics seeks partner for psoriasis candidate handed back by Boehringer
California-based AbGenomics is looking for a new partner for its humanised monoclonal antibody against CD-162, AbGn-168H, which was in development for the treatment of psoriasis and other immunological diseases under a collaboration with Boehringer Ingelheim.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- AbGenomics International, Inc.
- AbGenomics Corporation
- AbGenomics Holding Ltd.
- AltruBio Taiwan, Inc.